Division of Surgical Oncology, Department of Surgery, University of California, Davis Medical Center, Sacramento, California.
Comprehensive Cancer Center, University of California, Davis Medical Center, Sacramento, California.
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1767-1774. doi: 10.1158/1055-9965.EPI-20-0260.
Radiotherapy is used to treat many adolescent and young adult (AYA) and childhood cancer patients and is a risk factor for secondary breast cancer. While premenopausal breast cancer is inherently more aggressive, no studies to date have evaluated the characteristics and breast cancer-specific survival (BCSS) of premenopausal secondary breast cancer after radiotherapy in AYA and childhood cancer survivors.
Female patients ages 12 to 50 diagnosed with primary breast cancer from 1988 to 2014 ( = 107,751) were obtained from the California Cancer Registry and compared with similar aged patients with secondary breast cancer who were treated with radiotherapy for their primary tumor ( = 1,147) from ages 12 to 39. We examined BCSS using multivariable Cox proportional hazards regression.
The secondary breast cancer cohort was more likely to be Hispanic or Black, be 35 to 45 years of age, have earlier stage tumors, be higher grade, have no lymph node involvement, and be hormone receptor negative. All women showed worse BCSS for large tumor size, lymph node involvement, and hormone receptor-negative status. BCSS was worse for women with secondary breast cancer both overall (hazard ratio, 1.98; 95% confidence interval, 1.77-2.23) and in all subgroups considered. Associations were most pronounced in Hispanics, Asian/Pacific Islanders, and younger women, as well as those with earlier stage, lymph node-negative, and hormone receptor-positive disease.
BCSS is significantly decreased among all survivors of childhood and AYA cancer treated with radiotherapy that develop a secondary breast cancer, including women with good prognostic features.
Therefore, we may need to consider alternative and even more aggressive treatment in what were considered low-risk populations previously.
放疗被用于治疗许多青少年和年轻成人(AYA)及儿童癌症患者,也是继发性乳腺癌的一个风险因素。虽然绝经前乳腺癌本身更具侵袭性,但迄今为止,尚无研究评估 AYA 和儿童癌症幸存者接受放疗后的绝经前继发性乳腺癌的特征和乳腺癌特异性生存(BCSS)。
从加利福尼亚癌症登记处获得了 1988 年至 2014 年间诊断为原发性乳腺癌的 12 至 50 岁女性患者(n = 107751),并与年龄在 12 至 39 岁接受放疗治疗原发性肿瘤的年龄相似的继发性乳腺癌患者(n = 1147)进行比较。我们使用多变量 Cox 比例风险回归来检查 BCSS。
继发性乳腺癌队列更可能是西班牙裔或黑人,年龄在 35 至 45 岁,肿瘤分期较早,分级较高,无淋巴结受累,且激素受体阴性。所有女性的大肿瘤大小、淋巴结受累和激素受体阴性状态均预示着 BCSS 更差。患有继发性乳腺癌的女性总体上(风险比,1.98;95%置信区间,1.77-2.23)和所有考虑的亚组中,BCSS 均较差。在西班牙裔、亚洲/太平洋岛民和年轻女性以及分期较早、淋巴结阴性和激素受体阳性疾病的患者中,相关性更为显著。
接受放疗治疗的儿童和 AYA 癌症幸存者中,所有继发性乳腺癌患者的 BCSS 均显著降低,包括具有良好预后特征的患者。
因此,我们可能需要考虑替代方案,甚至在以前被认为是低风险人群中更具侵袭性的治疗方法。